Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.9152W HIGH $4.20
Volume
1.58 M
Value Traded
2.14 M
Short % Float
0.97%
+1.53%Week
-4.66%1 Month
+62.2%3 Month
+137.5%6 Month
-59.34%5 Year
-83.01%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
462.40 M
EPS (TTM)
-0.10
P/E Ratio
-
Ent. Value
451.09 M
Total Shares
173.83 M
Float Shares
131.65 M
Insiders
24.27%
Institutions
18.11%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ENTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Entera Bio Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Entera Bio Ltd.
422Total events
14Upcoming
67Tier-1 (high impact)
2018 to 2030Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationEB613 (oral PTH 1-34)FiledPresentation
EB613 Phase 2 data plenary poster at ASBMR 2026 (Fri-026)
osteoporosissource ↗
▲FDA Feedback ReceivedEB613 (oral PTH 1-34)FiledFDA Meeting
FDA alignment on 12-month registrational Phase 3 study to support NDA for EB613
postmenopausal women with osteoporosissource ↗
▼Equity OfferingCorporate
Oversubscribed $275 million private placement led by BVF Partners L.P.
▲FDA Feedback ReceivedEB613 (oral PTH 1-34)FiledFDA Meeting
FDA positive feedback on Phase 3 registrational protocol for EB613
postmenopausal osteoporosissource ↗
▲Poster PresentationEB612Presentation
Preclinical data for EB612 presented at ENDO 2026
hypoparathyroidismsource ↗
▲Poster PresentationEB618Presentation
Preclinical data for EB618 presented at ENDO 2026
obesity and metabolic disorderssource ↗
◆Poster PresentationEB612Presentation
Pre-Clinical Results for EB612 poster at ENDO 2026
hypoparathyroidismsource ↗
◆Oral PresentationEB613 (oral PTH 1-34)FiledPresentation
Late Breaking Oral Presentation of EB613 single tablet data at ENDO 2026
osteoporosissource ↗
◆Poster PresentationEB618Presentation
PK-PD Study Results for EB618 poster at ENDO 2026
obesity and metabolic disorderssource ↗
◆FDA Feedback ReceivedEB613 (oral PTH 1-34)FiledFDA Meeting
FDA feedback expected within 60 days of submission
postmenopausal osteoporosissource ↗
◆Oral PresentationEB613 (oral PTH 1-34)FiledPresentation
KOL webinar on osteoporosis treatment landscape and EB613 opportunity
osteoporosissource ↗
▼Equity OfferingCorporate
Pricing of $10.0 million direct investment by BVF Partners with potential for up to $24.5 million total proceeds
◆FDA Feedback ReceivedEB613 (oral PTH 1-34)FiledFDA Meeting
FDA feedback on streamlined Phase 3 protocol expected
postmenopausal women with osteoporosissource ↗
◆Oral PresentationPresentation
Entera Bio CEO fireside chat at Leerink Partners Global Healthcare Conference 2026
●IND SubmissionEB613 (oral PTH 1-34)FiledIND
Submitted streamlined Phase 3 protocol, SAP, and OLE synopsis to FDA under IND 505(b)(2)
postmenopausal osteoporosissource ↗
●IND SubmissionEB613 (oral PTH 1-34)FiledIND
Clinical Amendment submitted to IND in March 2026
postmenopausal osteoporosissource ↗
▲Partnership / LicenseLA-PTHCorporate
Expansion of collaboration between OPKO and Entera for oral LA-PTH
hypoparathyroidismsource ↗
▲Partnership / LicenseEB612Corporate
Expanded 50/50 partnership with OPKO for EB612
hypoparathyroidismsource ↗
▲Oral PresentationEB613 (oral PTH 1-34)FiledPresentation
Late-Breaking Oral Presentation at ENDO 2026 of comparative Phase 1 data
postmenopausal osteoporosissource ↗
▲First Patient DosedEB613 (oral PTH 1-34)FiledTrial
Phase 1 bridging study completed for EB613 single tablet formulation
osteoporosissource ↗
●NDA SubmissionEB613 (oral PTH 1-34)FiledRegulatory Filing
Final Phase 3 protocol submission to FDA
osteoporosissource ↗
◆Topline ReadoutEB613 (oral PTH 1-34)FiledClinical Data
Phase 1 bridging study results expected
post-menopausal women with osteoporosissource ↗
●Protocol AmendmentEB613 (oral PTH 1-34)FiledTrial
Final Phase 3 protocol submission to FDA planned
post-menopausal women with osteoporosissource ↗
▲FDA Feedback ReceivedFDA Meeting
FDA qualification of total hip BMD as a validated surrogate endpoint for novel osteoporosis drug development
osteoporosissource ↗
▲Preclinical PoCEB612Preclinical
Positive preclinical PK/PD data for long-acting PTH analog in EB612 program
hypoparathyroidismsource ↗
▲FDA Feedback ReceivedEB613 (oral PTH 1-34)FiledFDA Meeting
FDA broad qualification of BMD as regulatory endpoint for anti-osteoporosis drugs
post-menopausal women with osteoporosissource ↗
◆Oral PresentationPresentation
CEO Miranda Toledano to participate in fireside chat at 8th Annual Evercore ISI Healthcare Conference
▲PK PD DataLA-PTHClinical Data
Favorable PK/PD data for oral LA-PTH reported in December 2025
hypoparathyroidismsource ↗
◆Preclinical PoCEB612Preclinical
First PK/PD pre-clinical data for long-acting PTH analog tablet candidate
hypoparathyroidismsource ↗
▲FDA Feedback ReceivedEB613 (oral PTH 1-34)FiledFDA Meeting
FDA issued broad qualification of BMD as surrogate endpoint
postmenopausal women with osteoporosissource ↗
▲First Patient DosedEB613 (oral PTH 1-34)FiledTrial
Phase 1 bridging study initiated
osteoporosissource ↗
▲Trial InitiationEB613 (oral PTH 1-34)FiledTrial
Phase 1 bridging study initiated
post-menopausal women with osteoporosissource ↗
▲Poster PresentationEB613 (oral PTH 1-34)FiledPresentation
Poster presentation at NAMS 2025 of post-hoc analysis of Phase 2 trial of EB613
postmenopausal osteoporosissource ↗
◆Oral PresentationEB613 (oral PTH 1-34)FiledPresentation
Presentation of new Phase 2 data of EB613 at NAMS 2025 Annual Meeting
osteoporosissource ↗
◆Trial InitiationEB613 (oral PTH 1-34)FiledTrial
Phase 1 clinical trial of Next-Gen EB613 planned to begin
osteoporosissource ↗
Past FDA Catalysts and PDUFA Decisions
How ENTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-09 | EB613 (oral PTH(1-34) tablet) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D23 / 100
Pipeline Score
$2M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 87%
Micro Cap(rank 574 of 660)
Percentile Rank
Entera Bio Ltd. faces pipeline headwinds (23/100), with $56M risk-adjusted pipeline value, led by EB612 in Hypoparathyroidism (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EB612 Small moleculeCompletedNCT03516773 | Hypoparathyroidism | Phase 2 | COMPLETED | 20 | Feb 24, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every ENTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| EB613 | osteoporosis | Phase 2 | 2026-10-08 | 161-patient; 6-month; produced rapid dose-proportional increases in biochemical markers of bone formation; reductions in markers of bone resorption; increases in lumbar spine, total hip, and femoral neck BMDRead More | Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Toledano Miranda JayneDirector, Officer (Chief Executive Officer) | Grant/Award | 347,567 774,142 held | $0.00 | 07/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ENTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BVF INC/IL | 0.1 % | 4.29 M | 2.42 M |
ENTX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ENTX ranks across every disease it competes in
Competitive Position is a premium feature
See how ENTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialENTX News
ENTX▲ +10%today
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
Entera Bio Ltd. announced an additional presentation of its Phase 3 study design for EB613 at the ASBMR 2026 Annual Meeting. The presentation will detail the methodology for a randomized, double-blind trial aimed at treating postmenopausal women with osteoporosis. This follows the acceptance of Phase 2 data for EB613, showcasing its potential benefits in osteoporosis treatment.
Read more →ENTX▲ +10%today
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Entera Bio Ltd. has appointed Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill brings over 35 years of experience in biopharmaceuticals, succeeding Yonatan Malca. Her expertise is expected to aid Entera's late-stage clinical execution and commercial strategy, particularly for their product EB613 aimed at osteoporosis.
Read more →ENTXEntera to Participate in Upcoming Fall Investor Conferences
Entera Bio Ltd. announced that CEO Miranda Toledano will participate in several upcoming investor conferences, including the Cantor Global Healthcare Conference and the Guggenheim Securities Healthcare Innovation Conference. The company is advancing its pipeline of oral peptide therapies, with its lead candidate, EB613, showing promising results in clinical trials. However, the company acknowledges various risks associated with its forward-looking statements.
Read more →ENTXEntera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
Entera has appointed Dr. Riccardo Paolo Camisasca as Chief Medical Officer, bringing 30 years of experience in global pharmaceutical research and clinical development. His previous roles include positions at Sumitomo Pharma, Takeda, and Novartis. This appointment is expected to bolster Entera's clinical execution team and support the planned initiation of the EB613 Phase 3 trial.
Read more →ENTX▲ +5.9%on this news
Entera Announces Second Quarter 2026 Financial Results and Business Updates
Entera has announced its financial results for the second quarter of 2026, highlighting FDA alignment on a 12-month registrational Phase 3 study for EB613, an oral anabolic tablet aimed at postmenopausal women with osteoporosis. Additionally, the company successfully completed a $275 million private placement led by BVF Partners L.P., reflecting strong market confidence.
Read more →ENTXEntera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
Entera Bio announced that data from its Phase 2 trial of EB613, an oral PTH(1-34) treatment for osteoporosis, has been selected for presentation at the ASBMR 2026 Annual Meeting. The trial demonstrated significant anabolic effects in postmenopausal women at high risk for fractures. Entera plans to initiate a Phase 3 trial to support a New Drug Application.
Read more →ENTXEntera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
Entera Bio Ltd. announced that its CEO, Miranda Toledano, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026. The event will be held in Boston and will include a live webcast. Entera is known for developing oral peptide therapies for various medical needs.
Read more →ENTXGreenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE
Entera Bio Ltd. has successfully completed a $275 million oversubscribed private placement financing, advised by Greenberg Traurig. This funding will extend the company's cash runway into 2030 and support Phase 3 registrational studies for EB613, the first oral PTH (1-34) peptide tablet aimed at treating osteoporosis. The financing marks a significant milestone as the largest disclosed Israeli biotech PIPE to date.
Read more →ENTX▲ +91.2%on this newsshared move
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
Entera Bio Ltd. has announced a successful oversubscribed private placement, raising approximately $275 million. The funds will support Phase 3 registrational studies for EB613, an oral treatment for osteoporosis, and extend the company's cash runway into 2030. The placement is led by BVF Partners L.P. and includes several new investors.
Read more →ENTX▲ +22.3%on this news
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
Entera Bio has received positive feedback from the FDA regarding its Phase 3 study protocol for EB613, an oral anabolic tablet for treating osteoporosis in postmenopausal women. The trial will involve approximately 750 participants and aims to demonstrate significant increases in hip bone mineral density after 12 months. The NDA submission is anticipated based on these results, with topline data expected in late 2028.
Read more →ENTXEntera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
Entera Bio Ltd. presented promising preclinical results for its oral peptides EB612 and EB618 at ENDO 2026. EB612, designed for hypoparathyroidism, was found to restore calcium levels effectively in multiple models, while EB618 showed robust pharmacokinetics and positive effects on blood glucose levels in non-human primates. Both therapies are being developed in collaboration with OPKO Health and are progressing towards IND submissions, with EB612 expected to file in late 2026.
Read more →ENTXENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
Entera Bio Ltd. presented promising Phase 1 data for its single tablet EB613 at ENDO 2026, demonstrating comparable pharmacokinetic and pharmacodynamic profiles to Forteo® and multi-tablet EB613. The data supports the advancement of EB613 into a planned Phase 3 study for treating osteoporosis in postmenopausal women. The single tablet format may improve patient adherence and acceptance.
Read more →ENTXEntera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
Entera Bio Ltd. announced that its EB613 tablet, an oral PTH(1-34) anabolic treatment for osteoporosis, has been selected for a Late Breaking Oral Presentation at the ENDO 2026 Annual Meeting. The presentation will showcase new clinical data supporting EB613 as the final candidate for a planned Phase 3 study in postmenopausal women. Additionally, other abstracts from Entera's oral peptide pipeline have been accepted for presentation.
Read more →ENTX▼ -5.1%on this news
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Entera Bio Ltd. announced its financial results for Q1 2026, highlighting significant progress in its oral peptide programs, including submissions for EB613, EB612, and EB618 at ENDO2026. The company has submitted a streamlined Phase 3 protocol for EB613 focused on treating postmenopausal osteoporosis and expanded its partnership with OPKO for EB612, aimed at hypoparathyroidism. Despite a net loss of $3.5 million, Entera's increased cash reserves bolster its operational capabilities for upcoming clinical trials. The company remains committed to innovation in underserved therapeutic areas.
Read more →ENTXEntera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Entera Bio Ltd. is set to host a Key Opinion Leader webinar on April 20, 2026, focusing on osteoporosis treatment and its candidate EB613. The event will feature discussions with leading experts on women's bone health and the current treatment landscape. EB613 has shown positive results in clinical trials, positioning it as a potential first oral anabolic therapy for osteoporosis.
Read more →ENTX▲ +10.5%on this news
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Entera Bio Ltd. has announced a private placement led by BVF Partners, raising approximately $10 million, with the potential for total proceeds of $24.5 million. The funds will be used to initiate a Phase 3 study of EB613, an oral treatment for postmenopausal women with osteoporosis. The placement is set to close around April 2, 2026.
Read more →ENTX▼ -11.5%on this newsshared move
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Entera Bio announced its financial results for 2025, highlighting significant progress in its pipeline, including the submission of a Phase 3 protocol for EB613, an oral anabolic peptide for osteoporosis. The company aims to make anabolic treatment more accessible. Despite a net loss of $11.4 million, Entera is optimistic about its innovative oral peptide therapies.
Read more →ENTXEntera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
Entera Bio has submitted a streamlined Phase 3 protocol to the FDA for EB613, an oral treatment for postmenopausal osteoporosis. The study aims to evaluate the drug's efficacy in increasing total hip bone mineral density (BMD) over 12 months. The new single tablet formulation is expected to enhance patient compliance and accelerate the path to approval, with topline results anticipated in late 2028.
Read more →ENTXEntera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
Entera Bio Ltd. announced that CEO Miranda Toledano will participate in the Leerink Partners Global Healthcare Conference 2026. The event will take place on March 11, 2026, in Miami, Florida. A live webcast will be available for those unable to attend in person, with a replay accessible for 365 days. Entera is known for its innovative oral peptide therapies.
Read more →About Entera Bio Ltd.
HeadquartersKIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM, 9112002
BIOPHARMAWATCH ELITE PLUS
Trade the next ENTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime